Friday, September 22, 2017
News Recap:
Access to Treatment:
This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad). Imagine being sick or on treatment in one of these stricken areas!
In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...
Elevated hepatitis B virus core-related antigen levels significantly increased the risk for progression to cirrhosis among patients with chronic hepatitis B who are hepatitis B e antigen-negative and are not receiving nucleos(t)ide analogue therapy, according to recently published data.
“Recently, various indices of liver fibrosis based on clinical and biological data have been reported to be useful predictors of fibrosis in liver disease,” Toshifumi Tada
Friday, August 25, 2017
News Recap:
Public health issues Hep B risk warning: Tools used in procedures such as callus scraping and cutting toenails could become contaminated with the virus and remain contaminated because of the sterilization practices followed. Public health authorities in Owen Sound have identified a local foot care clinic as a potential source of hepatitis B and are warning patients – other than orthotics patients – to consult a doc...
Tools used in procedures such as callus scraping and cutting toenails could become contaminated with the virus and remain contaminated because of the sterilization practices followed.
Public health authorities have identified a local foot care clinic as a potential source of hepatitis B and are warning patients – other than orthotics patients – to consult a doctor about getting tested for this disease.
Grey Bruce Health Unit issued a public advisory Tu
American Indian tribal citizens and other native peoples around the world are up to 10 times more likely to be infected with viral hepatitis than others in their countries, according to a global analysis of data on the liver-attacking diseases.
"Indigenous peoples worldwide are bearing a disproportionately high burden of hepatitis B, hepatitis C, or both,” said Raquel Peck, chief Executive of the London-based World Hepatitis Alliance.
Poverty, injectio
Friday, August 11, 2017
Research & Discoveries
Melbourne scientists are creating mini-livers in a dish
MELBOURNE scientists are creating mini livers in a dish using a world-first combination of human cells in an ambitious bid to grow liver tissue for transplants. The tiny experimental organs – developed from cells donated by cancer patients – will be used to test drugs and eventually treat disease.
Routine hospital tool found to predict poor ...
For patients with chronic hepatitis B (CHB), achievement of subcirrhotic range of liver stiffness (sc-LS) with antiviral therapy (AVT) is associated with reduced risk of hepatocellular carcinoma (HCC), according to a study published in the Journal of Gastroenterology and Hepatology.
During the study period, the researchers found that after 2 years of AVT, 67.0% of patients achieved sc-LS and 13.4% of patients developed HCC.
"The achievement of sc-LS af
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments into account.
In an attempt to explain the disparity between the two, suggestions have been made that lifestyle choices, such as drinking, smoking or even how much water a person drinks, might be the reason.
But Jing Sun, PhD, a pos...
Friday, July 14, 2017
News Recap
Local
New measures boost addiction treatment access in Victoria
New efforts to expand treatment for opioid users in Victoria are putting addiction specialists in hospital emergency departments and supporting family doctors who provide opioid substitution therapy for patients. The initiatives by Island Health and the Victoria Divisions of Family Practice are intended to dovetail with the work of the South Island Ra...
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank's oral selective immunomodulator, SB 9200, co-administered with Gilea
